Enzo Biochem

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in August 1976 and is headquartered in New York, NY.

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.5% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to the independent members of the Company's Board of Directors (the “Board”): Independent Directors, I am writing to address your seemingly hollow and tone-deaf response to my October 19th letter to recently-appointed directors Dr. Mary Tagliaferri and Dr. Ian B.

Bradley L. Radoff Issues Letter to the Independent Directors of Enzo Biochem Regarding Their Unwillingness to Acknowledge or Address Unprecedented Shareholder Unrest

GoTestMeNow™ enables individuals to instantly and privately access physician-authorized testing for a broad range of STIs including chlamydia, gonorrhea, syphilis, HIV-1/2, hepatitis and herpes

Enzo Biochem Expands GoTestMeNow™ Online Portal to Provide Patients with Direct Access to Private Testing for Sexually Transmitted Infections

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian B. Walters, who joined the Company's Board of Directors (the “Board”) in November 2020: Dr. Tagliaferri and Dr. Walters, As you likely know, I am one of Enzo's largest shareholders and have recently nominated two highly-qualifi

Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem

﻿Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer

HAMID ERFANAIN NAMED CHIEF EXECUTIVE OFFICER OF ENZO BIOCHEM TO ACCELERATE EXPANSION AND COMMERCIALIZATION OF KEY DIAGNOSTIC PLATFORMS

Enzo Biochem, Inc. (ENZ) Management on Q4 2021 Results - Earnings Call Transcript

Biosciences and diagnostics company Enzo Biochem Inc (NYSE: ENZ) reported fourth-quarter FY21 revenue growth of 27% year-on-year to $24.8 million. Revenue decreased 24% sequentially.

Enzo Biochem Clocks 27% Revenue Growth In Q4, Margin Remains Stable

Conference call and live webcast scheduled for today, Tuesday, October 12, 2021 at 8:30 am (ET)

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

Conference Call and Webcast Scheduled for October 12, 2021, 8:30 am ET

Enzo Biochem to Report Fourth Quarter and Full Year 2021 Financial Results and Business Update on Tuesday, October 12th

The stock price of Enzo Biochem, Inc. (NYSE: ENZ) increased by over 9% pre-market. This is why it happened.

ENZ Stock Increases Over 9% Pre-Market: Why It Happened

Enzo Biochem Inc (NYSE:ENZ) has received an expansion of its FDA Emergency Use Authorization (EUA) for its rapid extraction method on its Ampiprobe SARS-CoV-2 Test System to detect SARS-CoV-2, including the variants. The EUA enables laboratories to immediately use Enzo's faster extraction process to reduce the time by over one hour, or more than 25%, allowing more test runs on a single instrument.

FDA Expands EUA For Rapid Extraction On One COVID-19 Test System

Testing will be available through CLX Health's TrustAssure™ Global Testing Platform for international travelers from New York and New Jersey who will need to complete testing immediately prior to travel.

Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel

Enzo Biochem, Inc. (ENZ) Q3 2021 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Wednesday, June 9, 2021 at 4:30 PM (ET).

Enzo Biochem Reports Third Quarter Fiscal 2021 Results

Conference Call and Webcast Scheduled for June 9, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for June 9, 2021, 4:30 pm ET

Enzo Biochem to Report Third Quarter 2021 Financial Results on Wednesday, June 9

Company's specimen collection kit now available for use in COVID-19 testing in the U.S.

Enzo's Universal AMPICOLLECT™ Used on GENFLEX® Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization

The stock price of Enzo Biochem, Inc. (NYSE: ENZ) increased by over 30% pre-market. This is why it happened.

ENZ Stock Price Increases Over 30% Pre-Market: Why It Happened

Enzo Biochem, Inc. (ENZ) Q2 2021 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Monday, March 15, 2021 at 4:30 pm (ET)

Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates

NEW YORK, NY, March 04, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021.

Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference

Conference Call and Webcast Scheduled for March 15, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for March 15, 2021, 4:30 pm ET

Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15

NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”.

Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

NEW YORK, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of Directors has formed two new committees to support strategy related to targeting and execution of new business opportunities and development and support for new members of the leadership team within the Company. The establishment of the new board committees follows Enzo's recent announcement of quarterly organic growth of 47% on a year-over-year basis, EBITDA of approximately $1 million, and anticipation of setting the company on track to achieve full year profitability from operations.

ENZO BIOCHEM'S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES

CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today announced the preliminary results at the Company's...

Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc.

- Use of pooled sampling with Enzo's molecular diagnostic technology can help rapidly expand the number of people tested for COVID-19 -

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY'S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

CHEVY CHASE, Md., Dec. 31, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today acknowledged that each of Institutional Shareholder Services Inc....

Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend That Shareholders Vote AGAINST Elazar Rabbani at Enzo's Upcoming Annual Meeting

News for Enzo Biochem Stock (ENZ)